Intranasal "painless" human nerve growth factors slows amyloid neurodegeneration and prevents memory deficits in app x PS1 mice

Simona Capsoni, Sara Marinelli, Marcello Ceci, Domenico Vignone, Gianluca Amato, Francesca Malerba, Francesca Paoletti, Giovanni Meli, Alessandro Viegi, Flaminia Pavone, Antonino Cattaneo

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Nerve Growth Factor (NGF) is being considered as a therapeutic candidate for Alzheimer's disease (AD) treatment but the clinical application is hindered by its potent pro-nociceptive activity. Thus, to reduce systemic exposure that would induce pain, in recent clinical studies NGF was administered through an invasive intracerebral gene-therapy approach. Our group demonstrated the feasibility of a non-invasive intranasal delivery of NGF in a mouse model of neurodegeneration. NGF therapeutic window could be further increased if its nociceptive effects could be avoided altogether. In this study we exploit forms of NGF, mutated at residue R100, inspired by the human genetic disease HSAN V (Hereditary Sensory Autonomic Neuropathy Type V), which would allow increasing the dose of NGF without triggering pain. We show that "painless" hNGF displays full neurotrophic and anti-amyloidogenic activities in neuronal cultures, and a reduced nociceptive activity in vivo. When administered intranasally to APPxPS1 mice (n = 8), hNGFP61S/R100E prevents the progress of neurodegeneration and of behavioral deficits. These results demonstrate the in vivo neuroprotective and anti-amyloidogenic properties of hNGFR100 mutants and provide a rational basis for the development of "painless" hNGF variants as a new generation of therapeutics for neurodegenerative diseases.

Original languageEnglish
Article numbere37555
JournalPLoS One
Volume7
Issue number5
DOIs
Publication statusPublished - May 30 2012

Fingerprint

nerve growth factor
Memory Disorders
Nerve Growth Factors
Nerve Growth Factor
amyloid
Application programs
Amyloid
Data storage equipment
mice
Hereditary Sensory and Autonomic Neuropathies
therapeutics
pain
Neurodegenerative diseases
Pain
Gene therapy
Inborn Genetic Diseases
gene therapy
peripheral nervous system diseases
Medical Genetics
neurodegenerative diseases

ASJC Scopus subject areas

  • Agricultural and Biological Sciences(all)
  • Biochemistry, Genetics and Molecular Biology(all)
  • Medicine(all)

Cite this

Intranasal "painless" human nerve growth factors slows amyloid neurodegeneration and prevents memory deficits in app x PS1 mice. / Capsoni, Simona; Marinelli, Sara; Ceci, Marcello; Vignone, Domenico; Amato, Gianluca; Malerba, Francesca; Paoletti, Francesca; Meli, Giovanni; Viegi, Alessandro; Pavone, Flaminia; Cattaneo, Antonino.

In: PLoS One, Vol. 7, No. 5, e37555, 30.05.2012.

Research output: Contribution to journalArticle

Capsoni, S, Marinelli, S, Ceci, M, Vignone, D, Amato, G, Malerba, F, Paoletti, F, Meli, G, Viegi, A, Pavone, F & Cattaneo, A 2012, 'Intranasal "painless" human nerve growth factors slows amyloid neurodegeneration and prevents memory deficits in app x PS1 mice', PLoS One, vol. 7, no. 5, e37555. https://doi.org/10.1371/journal.pone.0037555
Capsoni, Simona ; Marinelli, Sara ; Ceci, Marcello ; Vignone, Domenico ; Amato, Gianluca ; Malerba, Francesca ; Paoletti, Francesca ; Meli, Giovanni ; Viegi, Alessandro ; Pavone, Flaminia ; Cattaneo, Antonino. / Intranasal "painless" human nerve growth factors slows amyloid neurodegeneration and prevents memory deficits in app x PS1 mice. In: PLoS One. 2012 ; Vol. 7, No. 5.
@article{228ec61f713941498d308aeee82e75b8,
title = "Intranasal {"}painless{"} human nerve growth factors slows amyloid neurodegeneration and prevents memory deficits in app x PS1 mice",
abstract = "Nerve Growth Factor (NGF) is being considered as a therapeutic candidate for Alzheimer's disease (AD) treatment but the clinical application is hindered by its potent pro-nociceptive activity. Thus, to reduce systemic exposure that would induce pain, in recent clinical studies NGF was administered through an invasive intracerebral gene-therapy approach. Our group demonstrated the feasibility of a non-invasive intranasal delivery of NGF in a mouse model of neurodegeneration. NGF therapeutic window could be further increased if its nociceptive effects could be avoided altogether. In this study we exploit forms of NGF, mutated at residue R100, inspired by the human genetic disease HSAN V (Hereditary Sensory Autonomic Neuropathy Type V), which would allow increasing the dose of NGF without triggering pain. We show that {"}painless{"} hNGF displays full neurotrophic and anti-amyloidogenic activities in neuronal cultures, and a reduced nociceptive activity in vivo. When administered intranasally to APPxPS1 mice (n = 8), hNGFP61S/R100E prevents the progress of neurodegeneration and of behavioral deficits. These results demonstrate the in vivo neuroprotective and anti-amyloidogenic properties of hNGFR100 mutants and provide a rational basis for the development of {"}painless{"} hNGF variants as a new generation of therapeutics for neurodegenerative diseases.",
author = "Simona Capsoni and Sara Marinelli and Marcello Ceci and Domenico Vignone and Gianluca Amato and Francesca Malerba and Francesca Paoletti and Giovanni Meli and Alessandro Viegi and Flaminia Pavone and Antonino Cattaneo",
year = "2012",
month = "5",
day = "30",
doi = "10.1371/journal.pone.0037555",
language = "English",
volume = "7",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "5",

}

TY - JOUR

T1 - Intranasal "painless" human nerve growth factors slows amyloid neurodegeneration and prevents memory deficits in app x PS1 mice

AU - Capsoni, Simona

AU - Marinelli, Sara

AU - Ceci, Marcello

AU - Vignone, Domenico

AU - Amato, Gianluca

AU - Malerba, Francesca

AU - Paoletti, Francesca

AU - Meli, Giovanni

AU - Viegi, Alessandro

AU - Pavone, Flaminia

AU - Cattaneo, Antonino

PY - 2012/5/30

Y1 - 2012/5/30

N2 - Nerve Growth Factor (NGF) is being considered as a therapeutic candidate for Alzheimer's disease (AD) treatment but the clinical application is hindered by its potent pro-nociceptive activity. Thus, to reduce systemic exposure that would induce pain, in recent clinical studies NGF was administered through an invasive intracerebral gene-therapy approach. Our group demonstrated the feasibility of a non-invasive intranasal delivery of NGF in a mouse model of neurodegeneration. NGF therapeutic window could be further increased if its nociceptive effects could be avoided altogether. In this study we exploit forms of NGF, mutated at residue R100, inspired by the human genetic disease HSAN V (Hereditary Sensory Autonomic Neuropathy Type V), which would allow increasing the dose of NGF without triggering pain. We show that "painless" hNGF displays full neurotrophic and anti-amyloidogenic activities in neuronal cultures, and a reduced nociceptive activity in vivo. When administered intranasally to APPxPS1 mice (n = 8), hNGFP61S/R100E prevents the progress of neurodegeneration and of behavioral deficits. These results demonstrate the in vivo neuroprotective and anti-amyloidogenic properties of hNGFR100 mutants and provide a rational basis for the development of "painless" hNGF variants as a new generation of therapeutics for neurodegenerative diseases.

AB - Nerve Growth Factor (NGF) is being considered as a therapeutic candidate for Alzheimer's disease (AD) treatment but the clinical application is hindered by its potent pro-nociceptive activity. Thus, to reduce systemic exposure that would induce pain, in recent clinical studies NGF was administered through an invasive intracerebral gene-therapy approach. Our group demonstrated the feasibility of a non-invasive intranasal delivery of NGF in a mouse model of neurodegeneration. NGF therapeutic window could be further increased if its nociceptive effects could be avoided altogether. In this study we exploit forms of NGF, mutated at residue R100, inspired by the human genetic disease HSAN V (Hereditary Sensory Autonomic Neuropathy Type V), which would allow increasing the dose of NGF without triggering pain. We show that "painless" hNGF displays full neurotrophic and anti-amyloidogenic activities in neuronal cultures, and a reduced nociceptive activity in vivo. When administered intranasally to APPxPS1 mice (n = 8), hNGFP61S/R100E prevents the progress of neurodegeneration and of behavioral deficits. These results demonstrate the in vivo neuroprotective and anti-amyloidogenic properties of hNGFR100 mutants and provide a rational basis for the development of "painless" hNGF variants as a new generation of therapeutics for neurodegenerative diseases.

UR - http://www.scopus.com/inward/record.url?scp=84861614275&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84861614275&partnerID=8YFLogxK

U2 - 10.1371/journal.pone.0037555

DO - 10.1371/journal.pone.0037555

M3 - Article

C2 - 22666365

AN - SCOPUS:84861614275

VL - 7

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 5

M1 - e37555

ER -